A5105881473- Diabetes Treatment and Management
- Diabetes Management and Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Effects of Vibration on Health
- Growth Hormone and Insulin-like Growth Factors
- Vehicle Noise and Vibration Control
- Pneumocystis jirovecii pneumonia detection and treatment
- Herpesvirus Infections and Treatments
- Noise Effects and Management
- Dementia and Cognitive Impairment Research
- Peptidase Inhibition and Analysis
- Hepatitis B Virus Studies
- Parathyroid Disorders and Treatments
- Liver Disease Diagnosis and Treatment
- Machine Learning in Healthcare
- Genomics and Rare Diseases
- Acupuncture Treatment Research Studies
- Hepatitis C virus research
- Viral Infections and Immunology Research
- Respiratory viral infections research
- Pancreatic function and diabetes
- Genetic Associations and Epidemiology
- Epilepsy research and treatment
- Genomic variations and chromosomal abnormalities
- Hemophilia Treatment and Research
Tianjin Nankai Hospital
2024-2025
Pfizer (United States)
2019-2025
Tianjin Hospital
2025
Tianjin Medical University
2024
Tianjin University of Traditional Chinese Medicine
2020-2024
University of Pennsylvania
2020-2024
University of Pennsylvania Health System
2024
California University of Pennsylvania
2020-2024
Weatherford College
2024
Anhui Medical University
2024
To evaluate the efficacy and tolerability of sitagliptin when added to insulin therapy alone or in combination with metformin patients type 2 diabetes.After a week placebo run-in period, eligible inadequately controlled on long-acting, intermediate-acting premixed (HbA1c > = 7.5% < 11%), were randomised 1:1 addition once-daily 100 mg matching over 24-week study period. The capped proportion plus at 75%. Further, 25%. dose remain stable throughout study. primary endpoint was HbA1c change from...
<h3>Background</h3> Serious safety concerns related to the use of antipsychotics have not decreased prescribing these agents nursing home (NH) residents. We assessed extent which resident clinical characteristics and institutional practice were associated with antipsychotic prescribing. <h3>Methods</h3> Antipsychotic was for a nationwide, cross-sectional population 16 586 newly admitted NH residents in 2006. computed facility-level rates based on previous year's (2005) patterns. Poisson...
Aim: To evaluate the efficacy and safety of adding sitagliptin or glimepiride to treatment regimen patients with type 2 diabetes mellitus inadequate glycaemic control on metformin monotherapy. Methods: Patients an HbA1c 6.5–9.0% while a stable dose (≥1500 mg/day) combined diet exercise for at least 12 weeks were randomized in double-blind manner receive either 100 mg daily (N = 516) (starting 1 mg/day up-titrated, based upon patient's self-monitoring blood glucose results, maximum up 6 519)...
Background The coexistence of transthyretin cardiac amyloidosis (ATTR‐CA) and aortic stenosis (AS) is increasingly recognized, but the clinical consequences are unclear. We aimed to characterize outcomes in AS plus ATTR‐CA compared with only or ATTR‐CA. Methods Results In a retrospective cohort study, patients only, were identified using all‐payer claims data (2015–2021). Eligible had ≥1 claim for (excluding light‐chain amyloidosis); aged ≥60 years; continuously enrolled medical plans ≥6...
A live attenuated zoster vaccine was licensed in the United States 2006 for prevention of shingles persons aged 60 years or older; indication extended 2011 to cover those 50–59 years. We assessed effectiveness (VE) against 8 after immunization at Kaiser Permanente Northern California. VE estimated by Cox regression with a calendar timeline that stratified birth year. adjusted demographics and time-varying covariates, including comorbidities immune compromise. From 2007 2014, 1.4 million...
Background Pneumocystis pneumonia (PCP) is an emerging infectious disease in immunocompromised hosts. However, the clinical characteristics of these patients are poorly understood mainland China. Methods We performed a retrospective study PCP from 2008 to 2012. Information was collected regarding manifestations, hospitalization, and outcome. A prognostic analysis using Cox regression model. Results 151 cases were included; 46 non-HIV 105 HIV cases. All-cause mortality (15.2% vs. 12.4%, p =...
The present study investigated the effect of transplanting endothelial progenitor cells (EPCs) transfected with vascular growth factor gene (VEGF165) into corpora cavernosa rats diabetic erectile dysfunction (ED).A rat model ED was constructed via intraperitoneal injection streptozotocin.After streptozotocin treatment, pre-treated EPCs from each three groups were transplanted their cavernosa.Our results, following intracavernosal pressure (ICP) monitoring, showed that ICP increased...
Background: Doxorubicin (DOX) is a potent chemotherapeutic agent with limited usage due to its cumulative cardiotoxicity. The Na + /H exchanger isoform 1 (NHE1) known regulator of oxidative stress, inflammation, and apoptosis. present study was designed investigate the possible protective effect cariporide (CAR), selective inhibitor NHE1, against DOX-induced cardiotoxicity in rats. Methods: Male Sprague-Dawley rats were intraperitoneally injected DOX induce cardiac toxicity CAR given orally...
OBJECTIVES: To quantify the use of cholinesterase inhibitors (ChEIs) and memantine in nursing home (NH) residents with dementia upon NH admission 3 months later to examine factors associated reduction therapy. DESIGN: Retrospective cohort study. SETTING: Nationwide sample U.S. NHs. PARTICIPANTS: Three thousand five hundred six newly admitted 2006. MEASUREMENTS: Data from pharmacy dispensing records were used determine ChEI medication at 3‐month follow‐up. The Minimum Set was resident‐...
Abstract Aims This study aimed to describe baseline characteristics and adherence among patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) treated tafamidis (VYNDAQEL®) in Japan using the Japanese Medical Data Vision (MDV) database. Methods results was a non‐interventional, retrospective cohort of adult (≥18 years old) MDV claims database diagnosed ATTR‐CM at least two prescriptions dose strength 4 × 20 mg/day between 1 March 2019 31 August 2021. The date first prescription defined...